In view of the fact that pancreatic cancer cells are highly resistant to chemotherapy, and gemcitabine (an FDA-approved drug) is only minimally effective against this malignancy, we investigated the role of CXCL12–CXCR4 signalling axis in pancreatic cancer chemoresistance. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.